Non-patient-related SARS-CoV-2 exposure from colleagues and household members poses the highest infection risk for hospital employees in a German university hospital: follow-up of the prospective Co-HCW seroprevalence study.


Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 08 10 2022
accepted: 30 01 2023
medline: 19 7 2023
pubmed: 15 2 2023
entrez: 14 2 2023
Statut: ppublish

Résumé

The Co-HCW study is a prospective, longitudinal, single-center observational study that aims to assess the SARS-CoV-2 seroprevalence and infection status in staff members of Jena University Hospital (JUH) in Jena, Germany. This follow-up study covers the observation period from 19th May 2020 to 22nd June 2021. At each of the three voluntary study visits, participants filled out a questionnaire regarding their SARS-CoV-2 exposure and provided serum samples to detect specific SARS-CoV-2 antibodies. Participants who were tested positive for antibodies against nucleocapsid and/or spike protein without previous vaccination and/or reported a positive SARS-CoV-2 PCR test were regarded to have been infected with SARS-CoV-2. Multivariable logistic regression modeling was applied to identify potential risk factors for infected compared to non-infected participants. Out of 660 participants that were included during the first study visit, 406 participants (61.5%) were eligible for the final analysis as their COVID-19 risk area (high-risk n = 76; intermediate-risk n = 198; low-risk n = 132) did not change during the study. Forty-four participants [10.8%, 95% confidence interval (95%CI) 8.0-14.3%] had evidence of a current or past SARS-CoV-2 infection detected by serology (n = 40) and/or PCR (n = 28). No association between SARS-CoV-2 infection and the COVID-19 risk group according to working place was detected. However, exposure to a SARS-CoV-2 positive household member [adjusted OR (AOR) 4.46, 95% CI 2.06-9.65] or colleague (AOR 2.30, 95%CI 1.10-4.79) was found to significantly increase the risk of a SARS-CoV-2 infection. Our results demonstrate that non-patient-related SARS-CoV-2 exposure posed the highest infection risk for hospital staff members of JUH.

Identifiants

pubmed: 36788173
doi: 10.1007/s15010-023-01995-z
pii: 10.1007/s15010-023-01995-z
pmc: PMC9928590
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1059

Informations de copyright

© 2023. The Author(s).

Références

Sabetian G, Moghadami M, Hashemizadeh Fard Haghighi L, et al. COVID-19 infection among healthcare workers: a cross-sectional study in southwest Iran. Virol J. 2021. https://doi.org/10.1186/s12985-021-01532-0 .
doi: 10.1186/s12985-021-01532-0 pubmed: 33731169 pmcid: 7968574
Alshamrani MM, El-Saed A, Al Zunitan M, Almulhem R, Almohrij S. Risk of COVID-19 morbidity and mortality among healthcare workers working in a Large Tertiary Care Hospital. Int J Infect Dis. 2021;109:238–43. https://doi.org/10.1016/j.ijid.2021.07.009 .
doi: 10.1016/j.ijid.2021.07.009 pubmed: 34242766 pmcid: 8260475
Piccoli L, Ferrari P, Piumatti G, et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Reg Health Eur. 2021;1:100013. https://doi.org/10.1016/j.lanepe.2020.100013 .
doi: 10.1016/j.lanepe.2020.100013 pubmed: 34173621
Abbas M, Robalo Nunes T, Martischang R, et al. Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. Antimicrob Resist Infect Control. 2021;10:7. https://doi.org/10.1186/s13756-020-00875-7 .
doi: 10.1186/s13756-020-00875-7 pubmed: 33407833 pmcid: 7787623
World Health Organization and International Labour Organization. COVID19: Occupational health and safety for health workers. Interim guidance 2 February 2021, Geneva 2021. Accessed 22 Sep 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-HCW_advice-2021-1 .
Whitworth J. COVID-19: a fast evolving pandemic. Trans R Soc Trop Med Hyg. 2020;114:241–8. https://doi.org/10.1093/trstmh/traa025 .
doi: 10.1093/trstmh/traa025 pubmed: 32198918
Abebe EC, Dejenie TA, Shiferaw MY, Malik T. The newly emerged COVID-19 disease: a systemic review. Virol J. 2020;17:96. https://doi.org/10.1186/s12985-020-01363-5 .
doi: 10.1186/s12985-020-01363-5 pubmed: 32641059 pmcid: 7341708
Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020;173:120–36. https://doi.org/10.7326/M20-1632 .
doi: 10.7326/M20-1632 pubmed: 32369541
Bahrs C, Kimmig A, Weis S, et al. Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff. Transbound Emerg Dis. 2022;69:720–30. https://doi.org/10.1111/tbed.14041 .
doi: 10.1111/tbed.14041 pubmed: 33605549
Jaudszus A, Pavlova M, Rasche M, Baier M, Moeser A, Lorenz M. One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis. BMC Pulm Med. 2022;22:101. https://doi.org/10.1186/s12890-022-01900-8 .
doi: 10.1186/s12890-022-01900-8 pubmed: 35331203 pmcid: 8943512
Robert Koch Institute. Zweite Aktualisierung der “Retrospektiven Phaseneinteilung der COVID-19-Pandemie in Deutschland.” Epidem Bullet. 2022;10:3–4.
Dzinamarira T, Nkambule SJ, Hlongwa M, et al. Risk factors for COVID-19 infection among healthcare workers. A first report from a living systematic review and meta-analysis. Saf Health Work. 2022;13:263–8. https://doi.org/10.1016/j.shaw.2022.04.001 .
doi: 10.1016/j.shaw.2022.04.001 pubmed: 35433073 pmcid: 9004144
Robert Koch Institute. COVID-19-Dashboard. Last accessed on 17 Jan 2023. https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4/page/Landkreise/ .
Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5:e475–83. https://doi.org/10.1016/S2468-2667(20)30164-X .
doi: 10.1016/S2468-2667(20)30164-X pubmed: 32745512 pmcid: 7491202
Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120–34. https://doi.org/10.1016/j.jhin.2020.11.008 .
doi: 10.1016/j.jhin.2020.11.008 pubmed: 33212126
Steensels D, Oris E, Coninx L, et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA. 2020;324:195–7. https://doi.org/10.1001/jama.2020.11160 .
doi: 10.1001/jama.2020.11160 pubmed: 32539107 pmcid: 7296458
Müller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and risk factors of COVID-19 in healthcare workers from 11 African countries: a scoping review and appraisal of existing evidence. Health Policy Plan. 2022;37:505–13. https://doi.org/10.1093/heapol/czab133 .
doi: 10.1093/heapol/czab133 pubmed: 34726740
Weis S, Scherag A, Baier M, et al. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study. Clin Microbiol Infect. 2021;27:470.e1-470.e9. https://doi.org/10.1016/j.cmi.2020.11.009 .
doi: 10.1016/j.cmi.2020.11.009 pubmed: 33221432
Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. 2021;12:63. https://doi.org/10.1038/s41467-020-20247-4 .
doi: 10.1038/s41467-020-20247-4 pubmed: 33397909 pmcid: 7782739

Auteurs

Christina Bahrs (C)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany. christina.bahrs@med.uni-jena.de.
Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. christina.bahrs@med.uni-jena.de.

Sebastian Weis (S)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.
Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI), Jena, Germany.

Miriam Kesselmeier (M)

Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Juliane Ankert (J)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.

Stefan Hagel (S)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.

Stephanie Beier (S)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.

Jens Maschmann (J)

Medical Executive Board, Würzburg University Hospital, Würzburg, Germany.

Andreas Stallmach (A)

Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases), Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Andrea Steiner (A)

Department for Occupational Health, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Michael Bauer (M)

Department of Anesthesiology and Intensive Care Therapy, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Wilhelm Behringer (W)

Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.

Michael Baier (M)

Institute of Medical Microbiology, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Cora Richert (C)

Department of Clinical Chemistry and Laboratory Medicine, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Florian Zepf (F)

Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Martin Walter (M)

Department of Psychiatry and Psychotherapy, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

André Scherag (A)

Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Michael Kiehntopf (M)

Department of Clinical Chemistry and Laboratory Medicine, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Bettina Löffler (B)

Institute of Medical Microbiology, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany.

Mathias W Pletz (MW)

Institute for Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, Am Klinikum 1, 07747, Jena, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH